International Clinical Trial: A Phase 2b Study Evaluating VH4011499 Capsid Inhibitor Long-Acting Injectable Plus Cabotegravir in Treatment Naive Adults (CINERGY)

Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07816250) titled 'A Phase 2b Study Evaluating VH4011499 Capsid Inhibitor Long-Acting Injectable Plus Cabotegravir in Treatment Naive Adults (CINERGY)' on Sept. 6.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: ViiV Healthcare

Condition: HIV Infections

Intervention: Drug: VH4011499 Drug: CAB

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: October 19, 2026

Target Sample Size: 200

To know more, visit https://clinicaltrials.gov/study/NCT07816250

Published by HT Dig...